mebendazole has been researched along with Peritoneal Neoplasms in 1 studies
Mebendazole: A benzimidazole that acts by interfering with CARBOHYDRATE METABOLISM and inhibiting polymerization of MICROTUBULES.
mebendazole : A carbamate ester that is methyl 1H-benzimidazol-2-ylcarbamate substituted by a benzoyl group at position 5.
Peritoneal Neoplasms: Tumors or cancer of the PERITONEUM.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Celestino Pinto, L | 1 |
| de Fátima Aquino Moreira-Nunes, C | 1 |
| Soares, BM | 1 |
| Burbano, RMR | 1 |
| de Lemos, JAR | 1 |
| Montenegro, RC | 1 |
1 other study available for mebendazole and Peritoneal Neoplasms
| Article | Year |
|---|---|
Mebendazole, an antiparasitic drug, inhibits drug transporters expression in preclinical model of gastric peritoneal carcinomatosis.
Topics: Antiparasitic Agents; Cell Line, Tumor; Drug Evaluation, Preclinical; Humans; Mebendazole; Membrane | 2017 |